Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Nicorette Strongmint vs NiQuitin Minimint Lozenge
NCT03130179Phase 1Completed
- Sponsor
- McNeil Laboratories
- Start
- Mar 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nicotine in tobacco dependence (2 arms), sponsored by McNeil Laboratories. Primary endpoints: Peak Plasma Concentration at 12 hours, Time to Maximum Concentration at 12 hours and 4 more. Started Mar 2017; status: completed.
02
Drugs
nicotine
03
Conditions
tobacco dependence
Beyond the preview
Go deeper on NCT03130179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03130179.